KOSDAQBiotech & Pharma217330

Cytogen

₩2,285▼ 0.44%2026-11-18 close
Market Cap
₩52.9B
Turnover
₩37,194,960
Volume
20K
Shares out.
23.1M
PER
—
PBR
1.7×
EPS
-₩513
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Growth Amid Narrowing Losses, Breakeven Still Ahead

Cytogen's revenue rose for three consecutive years from 2023 through 2025 and its operating margin improved every year, but its operating loss and net loss attributable to controlling shareholders both widened from a year earlier in the third quarter of 2026, so breakeven has not yet arrived.

  1. 1

    Revenue reached KRW 26.1 billion in 2025, up from KRW 761 million in 2022, and rose for three consecutive years from 2023 to 2025.

  2. 2

    The operating margin improved from -1,511.3% in 2022 to -31.3% in 2025, yet the company still posted an operating loss of KRW 8.16 billion in 2025.

  3. 3

    Third-quarter 2026 revenue of KRW 7.7 billion rose only 0.9% year on year, while the operating loss of KRW 1.35 billion and the net loss attributable to controlling shareholders of KRW 2.91 billion both widened from a year earlier.

  4. 4

    The KRW 5.2 billion convertible bond decided in May 2026 and the absorption merger of the wholly owned subsidiary, scheduled for October 1, 2026, are the main changes in capital and business structure.

  5. 5

    Because the last four quarters were net losses, no price-to-earnings ratio is calculated, and the price-to-book ratio sits above book value.

02

Business structure

Cytogen is a liquid biopsy company built on technology that separates and analyzes circulating tumor cells (CTCs) in a living state, and it has been listed on KOSDAQ since November 2018. Its core business divides into CTC-based diagnostics and research and preclinical services for pharmaceutical companies.

The company says it uses label-free capture based on cell size differences rather than antigen-antibody reactions, which it argues reduces damage to cancer cells.

At AACR 2026 in May 2026 it presented high-resolution CTC transcriptome analysis built on its proprietary Smart Biopsy platform, and it said this would expand its business toward a 'Total Oncology Solution'.

Its wholly owned subsidiary runs NIPT (non-invasive prenatal testing) and PGT (preimplantation genetic testing) for fertility and reproductive genetics, and the company cited that subsidiary's growth as a driver of 2025 revenue.

On July 29, 2026 the board approved absorbing this subsidiary through a small-scale merger at a 1.0 to 0.0 ratio without new share issuance, with the merger effective date scheduled for October 1, 2026.

New initiatives include a bio-robot division created in February 2026 and an expansion into precision and regenerative medicine. In the public sector, a November 2025 report said public procurement contracts won equaled about 9.6% of the prior year's total revenue.

In Japan, the company established a local entity in January 2025 and was selected as a participant in a major Japanese cancer project, which generated its first service revenue.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩7.6B-₩1.3B−17.2%
2025Q4₩6.5B-₩2.6B−39.1%
2026Q1₩6.4B-₩1.5B−23.1%
2026Q2₩6.8B-₩1.2B−17.8%
2026Q3₩7.7B-₩1.4B−17.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩800M-₩11.5B-₩18.8B−1511.3%−331.9%628.8%
2023₩3.2B-₩11.8B-₩15.8B−370.3%−29.6%39.5%
2024₩10.9B-₩10.7B-₩17.1B−97.8%−35.2%48.1%
2025₩26.1B-₩8.2B-₩12.3B−31.3%−34.7%72.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

Annual revenue grew from KRW 761 million in 2022 to KRW 3.18 billion in 2023 (up 318.6% year on year), KRW 10.9 billion in 2024 (up 242.6%), and KRW 26.1 billion in 2025 (up 138.8%). Revenue rose for three consecutive years from 2023 through 2025, and 2025 was the largest year in the 2022 to 2025 period.

The company attributed the 2025 increase to expanded new business results and higher results at its consolidated subsidiary.

Operating losses were KRW 11.5 billion in 2022, KRW 11.8 billion in 2023 (losses widened), KRW 10.7 billion in 2024 (losses narrowed), and KRW 8.16 billion in 2025 (losses narrowed), a loss-making run of four consecutive years from 2022 through 2025.

The operating margin improved every year, from -1,511.3% in 2022 to -370.3% in 2023, -97.8% in 2024 and -31.3% in 2025, a pattern that reflects revenue growth outpacing the increase in losses.

The net loss attributable to controlling shareholders was KRW 18.8 billion in 2022, KRW 15.8 billion in 2023 (narrowed), KRW 17.1 billion in 2024 (widened) and KRW 12.3 billion in 2025 (narrowed), and the total net loss including non-controlling interests was disclosed at the same amounts.

The debt-to-equity ratio fell from 628.8% in 2022 to 39.5% in 2023, then rose to 48.1% in 2024 and 72.9% in 2025. At the end of 2025, total equity was KRW 36 billion and total liabilities were KRW 26.2 billion.

Operating cash flow was negative every year, at -KRW 6.38 billion in 2022, -KRW 7.59 billion in 2023, -KRW 9.53 billion in 2024 and -KRW 6.95 billion in 2025.

Quarterly revenue fell from KRW 7.63 billion in the third quarter of 2025 to KRW 6.55 billion in the fourth quarter (down 14.1% quarter on quarter), then reached KRW 6.38 billion in the first quarter of 2026, KRW 6.83 billion in the second quarter and KRW 7.7 billion in the third quarter, with two straight quarters of increases after the first-quarter low.

The operating loss was largest in the fourth quarter of 2025 at KRW 2.56 billion, narrowed to KRW 1.47 billion and KRW 1.22 billion in the first and second quarters of 2026, then widened again to KRW 1.35 billion in the third quarter, which was also a wider loss than the KRW 1.31 billion of the year-earlier quarter.

The net loss attributable to controlling shareholders peaked at KRW 5.46 billion in the fourth quarter of 2025 and was KRW 2.91 billion in the third quarter of 2026, and the sum for the last four quarters is KRW 11.8 billion.

The company said first-half 2026 revenue of about KRW 13.2 billion was its largest first-half revenue on record, which matches the sum of the disclosed first- and second-quarter figures.

05

Industry analysis

CTC-based liquid biopsy analyzes cancer cells in blood rather than in tissue biopsies, and its uses are broadening toward monitoring treatment resistance, companion diagnostics and support for drug development.

At AACR 2026 in May 2026 the company presented detection of the AR-V7 variant, a marker linked to treatment resistance, in the blood of prostate cancer patients with high sensitivity, which it cited as evidence for real-time blood analysis.

For pharmaceutical customers, the demand case rests on using such tools to select patients who are more likely to respond to a drug during clinical trials.

In Korea, preclinical services for domestic pharmaceutical companies began in earnest in the period covered by the 2025 reports, and the company planned to widen its service scope and customer base in 2026.

Its technical differentiators are label-free capture that reduces cell damage and the combination of RNA velocity analysis with copy number variation analysis. Competition from overseas liquid biopsy companies is intense, and wider clinical use will depend on accumulated validation data and regulatory approvals.

Given that revenue is still small and operating losses continue, the business appears to be in an early commercialization phase. Whether the industry is moving into an expansion phase will depend on pharmaceutical R&D spending and on whether adoption of liquid biopsy tools increases.

06

Outlook

The company named a new bio-robot division, expansion in precision and regenerative medicine, and growth in fertility solutions through its subsidiary as the core of its restructuring after February 2026.

The absorption merger of the subsidiary has a scheduled merger effective date of October 1, 2026, with the merger registration set for October 15.

The company said the merger would combine its CTC-based precision medicine and reproductive genetic testing businesses and unify R&D, testing operations, sales and management systems to simplify decision-making.

On its Japan business, the company set out a plan to substantially expand operations there through 2026, and whether that plan showed up in third-quarter 2026 revenue is a point to verify in the annual report.

The proceeds of the KRW 5.2 billion convertible bond issued in May 2026 were disclosed as going to general operating funds and R&D investment. The first conversion price adjustment date is December 26, 2026, and it recurs every seven months after that.

The company presents CTC technology upgrades and expansion toward a Total Oncology Solution as its medium-term direction. A September 2026 media report also referred to expanding an equipment business based on its own technology, but contract size and timing need to be confirmed through company disclosures.

The next point to check is how post-merger consolidated results split between fertility diagnostics and CTC revenue.

07

Valuation

PER
—
PBR
1.7×
ROE
-32.7%
EPS
-₩513
BPS
₩1,344
Dividend per share
₩0

Cytogen has posted net losses attributable to controlling shareholders for the last four quarters, so its price-to-earnings ratio is not calculated. Because earnings-based multiples cannot be compared in this state, asset and equity-based measures are commonly used alongside them.

The price-to-book ratio sits above book value, and based on total equity of KRW 36 billion and a controlling-shareholder equity of KRW 35.6 billion at the end of 2025, the stock trades at a premium to net assets. Market capitalization also exceeds total equity.

The company pays essentially no dividend, so a dividend-based comparison does not apply. Whether the premium to net assets persists depends on how stock price moves and how total equity changes.

Total liabilities of KRW 26.2 billion at the end of 2025 equal roughly 73% of total equity, and the debt-to-equity ratio's rise since 2023 also shapes the equity-based reading. A direct comparison with sector multiples requires the same metrics from listed peers, and this commentary is limited to factual comparisons.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Sustained revenue growth

Revenue rose from KRW 761 million in 2022 to KRW 26.1 billion in 2025 and grew for three consecutive years from 2023 through 2025. Revenue increased in the second and third quarters of 2026 after the first-quarter low.

The company said first-half 2026 revenue of about KRW 13.2 billion was its largest first-half figure on record. The subsidiary, Japan operations and public procurement are cited as growth drivers.

Structural improvement in operating margin

The operating margin improved every year, from -1,511.3% in 2022 to -31.3% in 2025. Operating losses narrowed in the first and second quarters of 2026 compared with the preceding quarter. Total equity of KRW 36 billion at the end of 2025 provides a capital base.

Whether the improvement reflects revenue growth or cost reduction can be checked in the cost structure of the annual report.

Technology and business expansion

At AACR 2026 in May 2026 the company unveiled a high-resolution CTC transcriptome analysis method and said it would expand toward a Total Oncology Solution. In February 2026 it announced a bio-robot division and an expansion into precision and regenerative medicine.

The company said the merger would combine business capabilities, simplify decision-making and support shareholder value.

09

Bear factors

Continued losses and wider losses

Operating losses continued for four consecutive years from 2022 through 2025. The third-quarter 2026 operating loss of KRW 1.35 billion was wider than the KRW 1.31 billion of the year-earlier quarter. The net loss attributable to controlling shareholders over the last four quarters totals KRW 11.8 billion. Operating cash flow in 2025 was negative at -KRW 6.95 billion.

Slower growth and renewed loss widening in the third quarter

Third-quarter 2026 revenue of KRW 7.7 billion rose only 0.9% from a year earlier. Over the same period the net loss attributable to controlling shareholders widened to KRW 2.91 billion from KRW 1.62 billion.

The narrowing of the operating loss seen in the second quarter reversed in the third quarter, which is a weakness in the recent trend.

Capital structure and dilution burden

The debt-to-equity ratio rose from 39.5% in 2023 to 72.9% in 2025. In May 2026 the company issued a KRW 5.2 billion convertible bond, and the shares issuable on conversion equal 3.97% of total shares outstanding. The bond carries a 0% coupon and matures on May 26, 2031.

10

Risk factors

Dependence on the subsidiary

Revenue growth in 2025 was driven by new business results together with the subsidiary's expansion. The subsidiary could be affected by competition and the regulatory environment in fertility diagnostics.

After the merger the business is consolidated, so weakness in one unit feeds more directly into total consolidated results.

Dilution from convertible bonds

In the May 2026 convertible bond disclosure, the proceeds were stated for operating funds and R&D investment. The conversion price was set based on the one-month weighted average share price before the board resolution, among other measures.

Conversion price adjustment dates recur every seven months from December 26, 2026, so conversion terms can change with share price movements.

Management structure and legal history

The company said a management-rights dispute that lasted about a year was effectively ended by court rulings dismissing the claims in October 2025. In February 2026 the board moved to a single-CEO structure under Ahn Ji-hoon. Decisions are faster, but responsibility and judgment are concentrated in one person, which remains a risk.

11

What to watch next

  1. December 26, 2026

    The first conversion price adjustment date for the convertible bond. Whether the price is adjusted and how the number of shares issuable on conversion changes is the next point to check.

  2. Late March 2027

    The statutory filing deadline for the 2026 annual report. Full-year revenue, operating loss, post-merger consolidated structure and operating cash flow will be confirmed, and whether the widening losses seen in the third quarter of 2026 carried through the full year can be checked.

  3. After May 26, 2027

    The point at which the call right becomes exercisable, 12 months after issuance. The early redemption right becomes exercisable after 18 months.

  4. Mid-August 2027 (half-year report deadline)

    The point at which first-half 2027 revenue and operating loss are confirmed. It also shows how much the Japan business and public procurement contribute to revenue and whether merger effects appear in the quarterly trend.

12

Overall view

Cytogen's revenue grew to KRW 26.1 billion in 2025, and its operating margin improved from -1,511.3% in 2022 to -31.3% in 2025, so there has been change on both the top line and the margin.

However, operating losses and net losses attributable to controlling shareholders continue, and in the third quarter of 2026 the losses widened from a year earlier.

The net loss attributable to controlling shareholders over the last four quarters totals KRW 11.8 billion, and operating cash flow has been negative every year.

The absorption merger of the subsidiary, scheduled for October 1, 2026, brings the business structure together, while the KRW 5.2 billion convertible bond and the December 26, 2026 conversion price adjustment date are points to check on the capital side.

The bull factors are revenue growth, improving margins and the expansion axis, while the bear factors are continued losses, renewed loss widening in the third quarter, a rising debt-to-equity ratio and dilution burden.

Whether the company moves to breakeven can be checked against the 2026 annual report and first-half 2027 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. digitaltoday.co.kr
  2. sedaily.com
  3. supple.kr
  4. topdaily.kr
  5. mt.co.kr
  6. mt.co.kr
  7. hitnews.co.kr
  8. v.daum.net
  9. mt.co.kr
  10. digitaltoday.co.kr
  11. topdaily.kr
  12. thevc.kr
  13. m.news.nate.com
  14. sedaily.com
  15. digitaltoday.co.kr
  16. kr.investing.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis